Deficient amounts of thymosin after age 60 negatively impact our immune system.
TA1 is a very important Peptide (a short piece of a protein) that acts as a communicator to stimulate the production of the WBCs (white blood cells) that kill cancer cells, and viruses in the human body. We produce a large amount of Thymosin Alpha 1 as children, but as we age, the amount that is produced decreases. Because of deficient amounts of thymosin after age 60, our immunity decreases and we get more infections, and cancers as we age. You can see in the graph that the thymosin levels, shown in red, are very high in childhood and plunge around age thirty to critical levels around age 60. Correspondingly, as the thymosin alpha drops, the green line showing age related disease increases in response.
This subject would only be something to fret about as you age except for the fact that Thymosin alpha is a peptide that can be replaced to both prevent, and treat cancer, fibromyalgia, Lyme disease and muscle wasting diseases.
This is a relatively secret treatment for those patients who have poor immunity from age, other illness, and environmental contaminants. Surprisingly it has been around for over 50 years.
Where does Thymosin A work in the body? The thymus is a flat gland the size of a child’s breastbone and sits right behind the sternum and in front of the heart in the chest and it produces the T killer and T helper cells that kill cancer cells and viruses in our body throughout our life.
Animals have a thymus and when we eat the thymus of beef, it is called “sweetbreads”. The thymus of humans and other mammals shrink as we age and our immunity is less effective and efficient as we live beyond 30 and is obvious after age 60. The lack of the thymus production of T cells is the reason people do not respond as well to immunizations after age 60.
Thymosin alpha is the peptide that STIMULATES the growth of the thymus and the production of T cells from the thymus and is the key to staying immunologically healthy throughout life.
We now have the ability to inject thymosin alpha into aging and sick individuals to stimulate the activity of their own immune systems. Thymus Alpha1 is an endogenous human peptide, made up of a 28 amino acid fragments, which is known to helps restore immune function in the human body.
The thymus gland a specialized primary lymphoid organ of the immune system. Tests in china “demonstrated that thymosin alpha 1 can enhance the cellular immune function of elderly patients with malignant tumors.”
From frontiers in oncology an article: a Reappraisal of Thymosin Alpha 1 in cancer therapy. By Claudio Constantini et. Al. September 2019.
“Thymosin Alpha1 an endogenous peptide first isolated from the thymic tissue in the mid -sixties has gained considerable attention for its immunostimulatory activity that led to its application to diverse pathological conditions, including cancer.”
The success was especially noticeable when thymosin Alpha1 was used in combination with other chemo-and immune therapies. Cancer immunotherapy has made a significant jump following the development and clinical application of immune checkpoint inhibitors, by there were still major safety and efficacy concerns when they are used alone.
It seems to be that the combination of thymosin Alpha1 with other chemo and immune therapies provide the best, most enduring interventions with the least negative side effects.
So, the “rationale for the use of thymosin in cancer patients would be to enhance the immune capabilities with two aims: combating the tumor more efficiently and preventing opportunistic infections. “
“in addition, the use of thymosin would counteract the immunosuppressive side effects associated with conventional chemotherapy and radiotherapy.”
The study confirmed that the administration of T Alpha 1 did not result in additional toxicity, increasing the efficacy of the treatment.
“The experience with the tests of melanoma suggest three possible benefits from using T Alpha1: first, a direct effect on the tumor itself, second, an immune pairing for the activity of chemo and immunotherapies and third, immune maintenance for long term protection.”
“When combined with interferon, thymosin Alpha1 the results suggest a positive impact when treating Hep B and Hep C, likely promoting the optimal conditions for the full exploitation of the biological effects of interferon. The TAlpha1 seems to prevent a relapse in patients that achieved a virological response during therapy. It did not seem to impact the Hep B and C virus directly. So, the gain is in the immune system response.”
“Despite undisputable success, a broad application in clinical practice is still limited by two major shortcomings. First, the efficacy is limited as the majority of tumor patients do not respond to the therapy, a phenomenon that has been linked to the tumor characteristics of immune infiltration. Second, the safety is compromised by the emergence of immune-related adverse events that result from off target effects of an excessively activated immune system.”
This Health cast was written and presented by Dr. Kathy Maupin, M.D., Bio-identical Hormone Replacement Expert and Author, with Brett Newcomb, MA., LPC., Family Counselor, Presenter and Author. www.BioBalanceHealth.com.